Tang Zhen-Chu, Qu Qiang, Teng Xin-Qi, Zhuang Hai-Hui, Xu Wei-Xin, Qu Jian
Department of Neurology, The Second Xiangya Hospital of Central South University, Changsha, China.
Hunan Key Laboratory of Tumor Models and Individualized Medicine, The Second Xiangya Hospital of Central South University, Changsha, China.
Front Pharmacol. 2023 Jul 27;14:1192855. doi: 10.3389/fphar.2023.1192855. eCollection 2023.
In the past decade, super-enhancer (SE) has become a research hotspot with increasing attention on cancer occurrence, development, and prognosis. To illustrate the hotspots of SE in cancer research and its evolutionary tendency, bibliometric analysis was carried out for this topic. Literature published before Dec 31, 2022, in WOSCC, was systematically classified, and Citespace, bibliometric.com/app, and GraphPad Prism analyzed the data. After screening out inappropriate documents and duplicate data, 911 publications were selected for further bibliometric analysis. The top five research areas were Oncology (257, 28.211%), Cell Biology (210, 23.052%), Biochemistry Molecular Biology (209, 22.942%), Science Technology Other Topics (138, 15.148%), and Genetics Heredity (132, 14.490%). The United States of America (United States) has the highest number of documents (462, 50.71%), followed by China (303, 33.26%). Among the most productive institutions, four of which are from the United States and one from Singapore, the National University of Singapore. Harvard Medical School (7.68%) has the highest percentage of articles. Young, Richard A, with 32 publications, ranks first in the number of articles. The top three authors came from Whitehead Institute for Biomedical Research as a research team. More than two-thirds of the research are supported by the National Institutes of Health of the United States (337, 37.654%) and the United States Department of Health Human Services (337, 37.654%). And "super enhancer" (525), "cell identity" (258), "expression" (223), "cancer" (205), and "transcription factor" (193) account for the top 5 occurrence keywords. Since 2013, SE and cancer related publications have shown a rapid growth trend. The United States continues to play a leading role in this field, as the top literature numbers, affiliations, funding agencies, and authors were all from the United States, followed by China and European countries. A high degree of active cooperation is evident among a multitude of countries. The role of SEs in cell identity, gene transcription, expression, and inhibition, as well as the relationship between SEs and TFs, and the selective inhibition of SEs, have received much attention, suggesting that they are hot issues for research.
在过去十年中,超级增强子(SE)已成为一个研究热点,人们对癌症的发生、发展和预后的关注度不断提高。为了阐明SE在癌症研究中的热点及其发展趋势,对该主题进行了文献计量分析。系统分类了2022年12月31日前在WOSCC上发表的文献,并使用Citespace、bibliometric.com/app和GraphPad Prism对数据进行分析。在筛选出不合适的文献和重复数据后,选择了911篇出版物进行进一步的文献计量分析。前五个研究领域是肿瘤学(257篇,28.211%)、细胞生物学(210篇,23.052%)、生物化学与分子生物学(209篇,22.942%)、科学技术其他主题(138篇,15.148%)和遗传学与遗传(132篇,14.490%)。美国的文献数量最多(462篇,50.71%),其次是中国(303篇,33.26%)。在产出最多的机构中,有四家来自美国,一家来自新加坡国立大学。哈佛医学院的文章占比最高(7.68%)。理查德·A·杨以32篇出版物位居文章数量榜首。排名前三的作者来自怀特黑德生物医学研究所,是一个研究团队。超过三分之二的研究得到了美国国立卫生研究院(337篇,37.654%)和美国卫生与公众服务部(337篇,37.654%)的支持。“超级增强子”(525)、“细胞身份”(258)、“表达”(223)、“癌症”(205)和“转录因子”(193)是出现频率最高的前5个关键词。自2013年以来,SE与癌症相关的出版物呈快速增长趋势。美国在该领域继续发挥主导作用,因为顶级文献数量、所属机构、资助机构和作者均来自美国,其次是中国和欧洲国家。众多国家之间存在高度活跃的合作。SE在细胞身份、基因转录、表达和抑制中的作用,以及SE与转录因子之间的关系,以及对SE的选择性抑制,都受到了广泛关注,表明它们是研究的热点问题。